Hormonal
Combining GLP-1 receptor agonists (specifically liraglutide) with bariatric surgery (BS) or endoscopic bariatric therapy (EBT) significantly enhances weight loss and metabolic improvements compared to BS or EBT alone, particularly in patients experiencing weight regain or insufficient loss.
If you have had bariatric surgery or an endoscopic procedure but are regaining weight or hitting a plateau, adding a GLP-1 receptor agonist like liraglutide (titrated to 3mg daily) can significantly boost weight loss and metabolic health compared to the procedure alone. This is particularly effective for those who have regained weight after surgery. Expect potential gastrointestinal side effects like nausea, which often subside with dose titration. This approach is not a replacement for lifestyle changes but a powerful adjunct to them.
Adding liraglutide to EBT or BS provided significant weight loss when compared with EBT or BS alone. When changes in weight were compared across the studies, EBT with liraglutide showed a weight loss effect comparable to the net weight loss (ie, nadir weight loss after BS-regained weight) achieved following BS alone.
Why this rating
The review includes 11 studies (3 RCTs, 8 retrospective), but notes significant heterogeneity in study design, doses, and outcome measures, limiting the strength of a pooled conclusion.
Source
Weight Loss Effect of GLP-1 RAs With Endoscopic Bariatric Therapy and Bariatric Surgeries
Ahmad Imam et al. · Journal of the Endocrine Society · 2023
DOI 10.1210/jendso/bvad129
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →